Company: DNLI
Filing Date: 2025-04-17
Form Type: DEFA14A
Source: 0001714899-25-000088
Chunk: 0

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEFA14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
<div align='center'>________________________________________</div>

#### SCHEDULE 14A
<div align='center'>PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934

________________________________________</div>

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

| ¨ |     | Preliminary Proxy Statement                                                     |
| ¨ |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) |
| ¨ |     | Definitive Proxy Statement                                                      |
| x |     | Definitive Additional Materials                                                 |
| ¨ |     | Soliciting Material Pursuant to §240.14a‑12                                     |

#### Denali Therapeutics Inc.
<div align='center'>(Name of Registrant as Specified In Its Charter)</div>

Payment of Filing Fee (Check the appropriate box):

| x |     | No fee required                                                                                     |
| ¨ |     | Fee paid previously with preliminary materials                                                      |
| ¨ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a‑6(i)(1) and 0‑11 |